Replies to post #108211 on Biotech Values

[BTH]

I hope INCY's Phase 3 is positive because at near $2 billion market cap, there is 0.0000% room for error.

[DewDiligence]

The Bloomberg piece has another mistake that is significant, IMO: In reporting the 3Q10 sales of Enbrel, the article counts only the portion booked by PFE and overlooks the portion booked by AMGN.

[turtlepower]

RIGL does have a JAK drug though I doubt it is currently being developed for arthritis. Maybe they have plans for that indication down the road. And if AZN is a syk inhibitor then its not a late stage jak drug.

Not defending the writer:)